Neurotoxicity Research

, Volume 5, Issue 3, pp 165–176 | Cite as

Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease

  • Masato Asanuma
  • Ikuko Miyazaki
  • Norio Ogawa


Dopamine (DA)- or L-dihydroxyphenylalanine- (L-DOPA-) induced neurotoxicity is thought to be involved not only in adverse reaction induced by longterm L-DOPA therapy but also in the pathogenesis of Parkinson's disease. Numerousin vitro andin vivo studies concerning DA- or L-DOPA-induced neurotoxicity have been reported in recent decades. The reactive oxygen or nitrogen species generated in the enzymatical oxidation or auto-oxidation of an excess amount of DA induce neuronal damage and/or apoptotic or non-apoptotic cell death; the DA-induced damage is prevented by various intrinsic and extrinsic antioxidants. DA and its metabolites containing two hydroxyl residues exert cytotoxicity in dopaminergic neuronal cells mainly due to the generation of highly reactive DA and DOPA quinones which are dopaminergic neuron-specific cytotoxic molecules. DA and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. For example, the formation of DA quinone-α-synuclein consequently increases cytotoxic protofibrils and the covalent modification of tyrosine hydroxylase by DA quinones. The melanin-synthetic enzyme tyrosinase in the brain may rapidly oxidize excess amounts of cytosolic DA and L-DOPA, thereby preventing slowly progressive cell damage by auto-oxidation of DA, thus maintaining DA levels. Since tyrosinase also possess catecholamine-synthesizing activity in the absence of tyrosine hydroxylase (TH), the double-edged synthesizing and oxidizing functions of tyrosinase in the dopaminergic system suggest its potential for application in the synthesis of DA, instead of TH in the degeneration of dopaminergic neurons, and in the normalization of abnormal DA turnover in long-term L-DOPA-treated Parkinson's disease patients.


Dopamine L-DOPA Neurotoxicity Quinone Tyrosinase Parkinson's disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amicrelli F, A Gasbarri, L Masciocco, A Pompili, C Pacitti, G Carlucci, G Palumbo and M Miranda (1999) The effect of intrastriatal injection of liposome-entrapped tyrosinase on the dopamine levels in the rat brain.Cell. Mol. Biol. (Noisy-le-grand) 45, 1093–1097.Google Scholar
  2. Asanuma M, N Ogawa, S Nishibayashi, M Kawai, Y Kondo and E Iwata (1995) Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.Arch. Int. Pharmacodyn. Ther. 329, 221–230.PubMedGoogle Scholar
  3. Asanuma M, S Nishibayashi-Asanuma, I Miyazaki, M Kohno and N Ogawa (2001) Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals.J. Neurochem. 76, 1895–1904.PubMedGoogle Scholar
  4. Aubin N, O Curet, A Deffois and C Carter (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice.J. Neurochem. 71, 1635–1642.PubMedGoogle Scholar
  5. Baez S, Y Linderson and J Segura-Aguilar (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase.Biochem. Mol. Med. 54, 12–18.PubMedGoogle Scholar
  6. Baez S, J Segura-Aguilar, M Widersten, AS Johansson and B Mannervik (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes.Biochem J. 324, 25–28.PubMedGoogle Scholar
  7. Basma AN, EJ Moris, WJ Nicklas and HM Geller (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation.J. Neurochem. 64, 825–832.PubMedGoogle Scholar
  8. Ben-Shachar D, P Riderer and MB Youdim (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.J. Neurochem. 57, 1609–1614.PubMedGoogle Scholar
  9. Berman SB and TG Hastings (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease.J. Neurochem. 73, 1127–1137.PubMedGoogle Scholar
  10. Berman SB, MJ Zigmond and TG Hastings (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine.J. Neurochem. 67, 593–600.PubMedGoogle Scholar
  11. Borg DC (1974) Free radicals in the human nervous system.Adv. Neurol. 5, 277–286.PubMedGoogle Scholar
  12. Cadenas E, D Mira, A Brunmark, C Lind, J Segura-Aguilar and L Ernster (1988) Effect of superoxide dismutase on the autoxidation of various hydroquinones-a possible role of superoxide dismutase as a superoxide:semiquinone oxidoreductase.Free Radic. Biol. Med. 5, 71–79.PubMedGoogle Scholar
  13. Cadet JL, R Last, V Kostic, S Przedborski and V Jackson-Lewis (1991) Long-term behavioral and biochemical effects of intrastriatal injections of 6-hydroxydopamine.Brain Res. Bull. 26, 707–713.PubMedGoogle Scholar
  14. Casper D, U Yaparpalvi, N Rempel and P Werner (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicityin vitro.Neurosci. Lett. 289, 201–204.PubMedGoogle Scholar
  15. Cheng FC, JS Kuo, LG Chia and G Dryhurst (1996) Elevated 5-S-cysteinyldopamine/ homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.J. Neural Transm. 103, 433–446.PubMedGoogle Scholar
  16. Cohen G and RE Heikkila (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxy-dopamine, dialuric acid, and related cytotoxic agents.J. Biol. Chem. 249, 2447–2452.PubMedGoogle Scholar
  17. Colado MI, E O'Shea, R Granados, B Esteban, AB Martin and AR Green (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymetham phetamine (MDMA or ‘ecstasy’) administration.Br. J. Pharmacol. 126, 911–924.PubMedGoogle Scholar
  18. Conway KA, SJ Lee, JC Rochet, TT Ding, RE Williamson and PT Lansbury Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.Proc. Natl. Acad. Sci. USA 97, 571–576.PubMedGoogle Scholar
  19. Conway KA, JC Rochet, RM Bieganski and PT Lansbury Jr (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct.Science 294, 1346–1349.PubMedGoogle Scholar
  20. Diaz-Veliz G, S Mora, MT Dossi, P Gomez, C Arriagada, J Montiel, F Aboitiz and J Segura-Aguilar (2002) Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra.Pharmacol. Biochem. Behav. 73, 843–850.PubMedGoogle Scholar
  21. Double KL, L Zecca, P Costi, M Mauer, C Griesinger, S Ito, D Ben-Shachar, G Bringmann, RG Fariello, P Riederer and M Gerlach (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.J. Neurochem. 75 2583–2589.PubMedGoogle Scholar
  22. Drukarch B and FL van Muiswinkel (2000) Drug treatment of Parkinson's disease. Time for phase II.Biochem. Pharmacol. 59, 1023–1031.PubMedGoogle Scholar
  23. Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELL-DOPA trial. Earlier vs Later L-DOPA.Arch. Neurol. 56, 529–535.PubMedGoogle Scholar
  24. Ferger B, P Teismann, CD Earl, K Kuschinsky and WH Oertel (1999) Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.Naunyn Schmiedebergs Arch. Pharmacol. 360, 256–261.PubMedGoogle Scholar
  25. Filloux F and JJ Townsend (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection.Exp. Neurol. 119, 79–88.PubMedGoogle Scholar
  26. Foppoli C, R Coccia, C Cini and MA Rosei (1997) Catecholamines oxidation by xanthine oxidase.Biochim. Biophys. Acta 1334, 200–206.PubMedGoogle Scholar
  27. Fornstedt B, E Rosengren and A Carlsson (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.Neuropharmacology 25, 451–454.PubMedGoogle Scholar
  28. Giasson BI, JE Duda, IV Murray, Q Chen, JM Souza, HI Hurtig, H Ischiropoulos, JQ Trojanowski and VM Lee (2000) Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions.Science 290, 985–989.PubMedGoogle Scholar
  29. Gómez-Vargas M, S Nishibayashi-Asanuma, M Sanuma, Y Kondo, E Iwata and N Ogawa (1998) Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.Brain Res. 790, 202–208.PubMedGoogle Scholar
  30. Graham DG (1978) Oxidative pathways for catecholamines in th genesis of neuromelanin and cytotoxic quinones.Mol. Pharmacol. 14, 633–643.PubMedGoogle Scholar
  31. Halliwell B (1992) Reactive oxygen species and the central nervous systemJ. Neurochem. 59, 1609–1623.PubMedGoogle Scholar
  32. Haque ME, M Asanuma, Y Higashi, I Miyazaki, K Tanaka and N Ogawa (2003) Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells.Biochim. Biophys. Acta 1619, 39–52.Google Scholar
  33. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase.J. Neurochem. 64, 919–924.PubMedGoogle Scholar
  34. Hastings TG, DA Lewis and MJ Zigmond (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.Proc. Natl. Acad. Sci. USA 93, 1956–1961.PubMedGoogle Scholar
  35. Hearing VJ and TM Ekel (1976) Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation.Biochem. J. 157, 549–557.PubMedGoogle Scholar
  36. Heikkila RE and G Cohen (1973) 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate.Science 181, 456–457.PubMedGoogle Scholar
  37. Higashi Y, M Asanuma, I Miyazaki and N Ogawa (2000) Inhibition of tyrosinase reduces cell viability in catecholaminergic neuronal cells.J. Neurochem. 75, 1771–1774.PubMedGoogle Scholar
  38. Iida M, I Miyazaki, K Tanaka, H Kabuto, E Iwata-Ichikawa and N Ogawa (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.Brain Res. 838, 51–59.PubMedGoogle Scholar
  39. Ikemoto K, J Nagatsu, S Ito, RA King, A Nishimura and T Nagatsu (1998) Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?.Neurosci. Lett. 253, 198–200.PubMedGoogle Scholar
  40. Ito S and K Fujita (1982) Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical.Biochem. Pharmacol. 31, 2887–2889.PubMedGoogle Scholar
  41. Kastner A, EC Hirsch, O Lejeune, F Javoy-Agid, O Rascol and Y Agid (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?J Neurochem. 59, 1080–1089.PubMedGoogle Scholar
  42. Kerry N and C Rice-Evans (1999) Inhibition of peroxynitrite-mediated oxidation of dopamine by flavonoid and phenolic antioxidants and their structural relationships.J. Neurochem. 73, 247–253.PubMedGoogle Scholar
  43. Kirik D, C Rosenblad, C Burger, C Lundberg, TE Johansen, N Muzyczka, RJ Mandel and A Bjorklund (2002) Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system.J. Neurosci. 22, 2780–2791.PubMedGoogle Scholar
  44. Korytowski W, T Sarna, B Kalyanaraman and RC Sealy (1987) Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry.Biochim Biophys. Acta 924, 383–392.PubMedGoogle Scholar
  45. Korytowski W, T Sarna and M Zarba (1995) Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation.Arch. Biochem. Biophys. 319, 142–148.PubMedGoogle Scholar
  46. Kostrezewa RM (1999) Selective neurotoxins, chemical tool to probe the mind: the first thirty years and beyond.Neurotoxicity Res. 1, 3–25.Google Scholar
  47. Kostrzewa RM and D Jacobowit (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev.26, 199–288.PubMedGoogle Scholar
  48. Kostrzewa RM, JP Kostrzewa and R Brus (2000) Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum.Amino Acids 19, 183–1999.PubMedGoogle Scholar
  49. Kostrzewa RM, JP Kostrzewa and R Brus (2002) Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.Amino Acids 23, 57–63.PubMedGoogle Scholar
  50. Kuhn DM, RE Arthur Jr, DM Thomas and LA Elferink (1999) Tyrosine hydroxylase is inactivated by catechols-quinones aconverted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease.J. Neurochem. 73, 1309–1317.PubMedGoogle Scholar
  51. Lai CT and PH Yu (1997) Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminegic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.Biochem. Pharmacol. 53, 363–372.PubMedGoogle Scholar
  52. LaVoie MJ and TG Hastings (1999a) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.J. Neurosci. 19, 1484–1491.PubMedGoogle Scholar
  53. LaVoie MJ and TG Hastings (1999b) Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss.J. Neurochem. 73, 2546–2554.PubMedGoogle Scholar
  54. Lee HJ, SH Kim, KW Kim, JH Um, HW Lee, BS Chung and CD Kang (2001) Antipoptotic role of NF-KB in the auto-oxidized dopamine-induced apoptosis of PC12 cells.J. Neurochem. 76, 602–609.PubMedGoogle Scholar
  55. Lee M, D Hyun, B Halliwell and P Jenner (2001) Effect of the over-expression of wild-type or mutant α-synuclein on cell susceptibility to insult.J. Neurochem. 76, 998–1009.PubMedGoogle Scholar
  56. Li H and G Dryhurst (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's diseaseJ. Neurochem. 69, 1530–1541.PubMedGoogle Scholar
  57. Mattammal MB, R Stong, VM Lakshmi, HD, Chung and AH Stephenson (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease.J. Neurochem. 64, 1645–1654.PubMedGoogle Scholar
  58. Metodiewa D and C Koska (2000) Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview.Neurotoxicity Res. 1, 197–233.Google Scholar
  59. Miranda M and D Botti (1983) Harding-passey mouse-melanoma tyrosinase inactivation by reaction products and activation by L-epinephrine.Gen. Pharmacol. 14, 231–237.PubMedGoogle Scholar
  60. Miranda M, D Botti, A Bonfigli, T Ventura and A Arcadi (1984) Tyrosinase-like activity in normal human substantia nigra.Gen. Pharmacol. 15, 541–544.PubMedGoogle Scholar
  61. Miranda M, F Amicarelli, A Poma, AM Ragneli and A Arcadi (1988) Liposome-entrapped tyrosinase: a tool to investigate the regulation of the Raper-Mason pathway.Biochim. Biophys. Acta 966, 276–286.PubMedGoogle Scholar
  62. Murata M and I Kanazawa (1993) Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.Neurosci. Res. 16, 15–23.PubMedGoogle Scholar
  63. Mytilineou C, SK Han and G Cohen (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures.J. Neurochem. 61, 1470–1478.PubMedGoogle Scholar
  64. Nishibayashi S, M Asanuma, M Kohno, M Gómez-Vargas and N Ogawa (1996) Scavenging effects of dopamine agonists on nitric oxide radicals.J. Neurochem. 67, 2208–2211.PubMedGoogle Scholar
  65. Offen D, I Ziv, H Sternin, E Melamed and A Hochman (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.Exp. Neurol. 141, 32–39.PubMedGoogle Scholar
  66. Ogawa N, R Edmatsu, K Mizukawa, M Asanuma, M Kohno and A Mori (1993) Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.Adv. Neurol. 60, 242–250.PubMedGoogle Scholar
  67. Ogawa N, M Asanuma, Y Kondo, Y Kawada, M Yamamoto and A Mori (1994a) Differential effects of chronic L-DOPA treatment on lipid peroxydation in the mouse brain with or without pretreatment with 6-hydroxydopamine.Neurosci. Lett. 171, 55–58.PubMedGoogle Scholar
  68. Ogawa N, K Tanaka, M Asanuma, M Kawai, T Masumizu, M Kohno and A Mori (1994b) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicalsin vitro.Brain Res. 657, 207–213.PubMedGoogle Scholar
  69. Ogawa N, K Tanaka and M Asanuma (2000) Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.Neurochem. Res. 25, 755–758.PubMedGoogle Scholar
  70. Olanow CW and G Cohen (1992). The pathogenesis of Parkinson's disease, In: Olanow CW and AN Licherman (Eds),The Scientific Basis for the Treatment of Parkinson's Disease (The Parthenon Publishing Group, Lanes, U.K.), pp. 59–76.Google Scholar
  71. Ostrerova-Golts N, L Petrucelli, J Hardy, JM Lee, M Farer and B Wolozin (2000) The A53T α-synuclein mutation increases irondependent aggregation and toxicity.J. Neurosci. 20, 6048–6054.PubMedGoogle Scholar
  72. Pardo B, MA Mena, MJ Casarejos, CL Paino and JG De Yebenes (1995a) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.Brain Res. 682, 133–143.PubMedGoogle Scholar
  73. Pardo B, MA Mena and JG de Yebenes (1995b) L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells.J. Neurochem. 64, 576–582.PubMedGoogle Scholar
  74. Paris I, A Dagnino-Subiabre, K Marcelain, LB Bennett, P Caviedes, R Caviedes, CO Azar and J Segura-Aguilar (2001) Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line.J. Neurochem. 77, 519–529.PubMedGoogle Scholar
  75. Pilas B, T Sarna, B Kalyanaraman and HM Swartz (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide.Free Radic. Biol. Med. 4, 285–293.PubMedGoogle Scholar
  76. Przedborski S, V Jackson-Lewis, U Muthane, H Jiang, M Ferreira, AB Naini and S Fahn (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity.Ann. Neurol. 34, 715–723.PubMedGoogle Scholar
  77. Rios M, B Habecker, T Sasaka, G Eisenhofer, H Tian, S Landis, D Chikaraishi and S Roffler-Tarlov (1999) Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase.J. Neurosci. 19, 3519–3526.PubMedGoogle Scholar
  78. Rosei MA, C Blarzino, C Foppoli, L Mosca and R Cocia, (1994) Lipoxygenase-catalyzed oxidation of catecholamines.Biochem. Biophys. Res. Commun. 200, 344–350.PubMedGoogle Scholar
  79. Schultzberg M, J Segura-Aguilar and C Lind (1988) Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies.Neuroscience 27, 763–776.PubMedGoogle Scholar
  80. Schwabe K, G Lassmann, W Damerau and H Naundorf (1989) Protection of melanoma cells against superoxide radicals by melanins.J. Cancer.Res. Clin. Oncol. 115, 597–600.PubMedGoogle Scholar
  81. Segura-Aguilar J and C Lind (1989) On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase.Chem. Biol. Interact. 72, 309–324.PubMedGoogle Scholar
  82. Segura-Aguilar J, S Baez, M Widersten, CJ Welch and B Mannervik (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome.J. Biol. Chem. 272, 5727–5731.PubMedGoogle Scholar
  83. Segura-Aguilar J, D Metodiewa and CJ Welch (1998) Metabolic activation of dopamineo-quinones too-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects.Biochim. Biophys. Acta 1381, 1–6.PubMedGoogle Scholar
  84. Smythies J (1999) The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.Neurotoxicity Res. 1, 27–39.Google Scholar
  85. Solano F, VJ Hearing and JC Garcia-Borron (2000) Neurotoxicity due too-quinone: neuromelanin formation and possible mechanisms foro-quinone detoxification.Neurotoxicity Res. 1, 153–169.Google Scholar
  86. Spencer JP, A Jenner, J Butler, OI Aruoma, DT Dexter, P Jenner and B Halliwell (1996) Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopaminein vitro: implications for Parkinson's disease.Free Radic. Res. 24, 95–105.PubMedGoogle Scholar
  87. Spencer JP, P Jenner, SE Daniel, AJ Lees, DC Marsden and B Halliwell (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.J. Neurochem. 71, 2112–2122.PubMedGoogle Scholar
  88. Sulzer D and L Zecca (2000) Intraneuronal dopamine-quinone synthesis: a review.Neurotoxicity Res. 1, 181–195.Google Scholar
  89. Sulzer D, J Bogulavsky, KE Larsen, G Behr, E Karatekin, MH Kleinman, N Turro, D Krantz, RH Edwards, LA Greene and L Zecca (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.Proc. Natl. Acad. Sci. USA 97, 11869–11874.PubMedGoogle Scholar
  90. Tabrizi SJ, M Orth, JM Wilkinson, JW Taanman, TT Warner, JM Cooper and AH Schapira (2000) Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity.Hum. Mol. Genet. 9, 2683–2689.PubMedGoogle Scholar
  91. Takashima H, M Tsujihata, M Kishikawa and WJ Freed (1999) Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.Exp. Neurol. 159, 98–104.PubMedGoogle Scholar
  92. Tanaka M, A Sotomatsu, T Yoshida and S Hirai (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron.Neurosci. Lett. 183, 116–119.PubMedGoogle Scholar
  93. Teismann P and B Ferger (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.Synapse 39, 167–174.PubMedGoogle Scholar
  94. Terasaka H, A Tamura, F Takayama, M Kashimata, K Ohtomo, M Machino, S Fujisawa, M Toguchi, Y Kanda, S Kunii, K Kusama, A Ishino, S Watanabe, K Satoh, H Takano, M Takahama and H Sakagami (2000) Induction of apoptosis by dopamine in human oral tumor cell lines.Anticancer Res. 20, 243–250.PubMedGoogle Scholar
  95. Tief K, M Hahne, A Schmidt and F Beermann (1996a) Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain.Eur. J. Biochem. 241, 12–16.PubMedGoogle Scholar
  96. Tief K, A Schmidt, A Aguzzi and F Beermann (1996b) Tyrosinase is a new marker for cell populations in the mouse neural tube.Dev. Dyn. 205, 445–456.PubMedGoogle Scholar
  97. Tief K, A Schmidt and F Beermann (1997) Regulation of the tyrosinase promoter in transgenic mice: expression of a tyrosinase-lacZ fusion gene in embryonic and adult brain.Pigment Cell Res. 10, 153–157.PubMedGoogle Scholar
  98. Tief K, A Schmidt and F Beermann (1998) New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain.Mol. Brain Res. 53, 307–310.PubMedGoogle Scholar
  99. Tse DC, RL McCreery and RN Adams (1976) Potential oxidative pathways of brain catecholamines.J. Med. Chem. 19, 37–40.PubMedGoogle Scholar
  100. van der Putten H, KH Wiederhold, A Probst, S Barbieri, C Mistl, S Danner, S Kauffmann, K Hofele, WP Spooren, MA Ruegg, S Lin, P Caroni, B Sommer, M Tolnay and G Bilbe (2000) Neuropathology in mice expressing human α-synuclein.J. Neurosci. 20, 6021–6029.PubMedGoogle Scholar
  101. Volles MJ, SJ Lee, JC Rochet, MI Shtilerman, TT Ding, JC Kessler and PT Lansbury Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.Biochemistry 40, 7812–7819.PubMedGoogle Scholar
  102. Wakamatsu K, S Ito and T Nagatsu (1991) Cysteinyldopamine is not incorporated into neuromelanin.Neurosci. Lett. 131, 57–60.PubMedGoogle Scholar
  103. Walkinshaw G and CM Waters (1995) Induction of apoptosis in carecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.J. Clin. Invest. 95, 2458–246.PubMedGoogle Scholar
  104. Weingarten P, J Bermak and QY Zhou (2001) Evidence for nonoxidative dopamine cytotoxicity: potent activation of NF-KB and lack of protection by anti-oxidants.J. Neurochem. 76, 1794–1804.PubMedGoogle Scholar
  105. Xu J, SY Kao, FJ Lee, W Song, LW Jin and BA Yankner (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.Nature Med. 8, 600–606.PubMedGoogle Scholar
  106. Xu Y, AH Stokes, WM Freeman, SC Kumer, BA Vogt and KE Vrana (1997) Tyrosinase mRNA is expressed in human substantia nigra.Mol. Brain Res. 45, 159–162.PubMedGoogle Scholar
  107. Xu Y, AH Stokes, R Roskoski Jr and KE Vrana (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase.J. Neurosci. Res. 54, 691–697.PubMedGoogle Scholar
  108. Yoshioka M, K Tanaka, I Miyazaki, N Fujita, Y Higashi, M Asanuma and N Ogawa (2002) The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.Neurosci. Res. 43, 259–267.PubMedGoogle Scholar
  109. Zareba M, A Bober, W Korytowski, L Zecca and T Sarna (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems.Biochim. Biophys. Acta 1271, 343–348.PubMedGoogle Scholar
  110. Zecca L and HM Swartz (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin.J. Neural Transm. Park. Dis. Dement. Sect. 5, 203–213.PubMedGoogle Scholar
  111. Zecca L, R Pietra, C Goj, C Mecacci, D Radice and E Sabbioni (1994) Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain.J. Neurochem. 62, 1097–1101.PubMedGoogle Scholar
  112. Zecca L, T Shima, A Stroppolo, C Goj, GA Battiston, R Gerbasi, T Sarna and HM Swartz (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.Neuroscience 73, 407–415.PubMedGoogle Scholar
  113. Zecca L, R Fariello, P Riederer, D Sulzer, A Gatti and D Tampellini (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's diseaseFEBS Lett. 510, 216–220.PubMedGoogle Scholar

Copyright information

© FP Graham Publishing Co 2003

Authors and Affiliations

  1. 1.Department of Brain ScienceOkayama University Graduate School of Medicine and DentistryOkayamaJapan

Personalised recommendations